CY1108018T1 - Μεθοδος και φαρμακευτικο σκευασμα για την αντιμετωπιση της αντιστασης στα αντιυπερτασικα φαρμακα και για σχετικες παθησεις - Google Patents
Μεθοδος και φαρμακευτικο σκευασμα για την αντιμετωπιση της αντιστασης στα αντιυπερτασικα φαρμακα και για σχετικες παθησειςInfo
- Publication number
- CY1108018T1 CY1108018T1 CY20071100916T CY071100916T CY1108018T1 CY 1108018 T1 CY1108018 T1 CY 1108018T1 CY 20071100916 T CY20071100916 T CY 20071100916T CY 071100916 T CY071100916 T CY 071100916T CY 1108018 T1 CY1108018 T1 CY 1108018T1
- Authority
- CY
- Cyprus
- Prior art keywords
- patients
- melatonin
- drugs
- resistance
- antipherensic
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 abstract 3
- 239000002220 antihypertensive agent Substances 0.000 abstract 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract 3
- 229960003987 melatonin Drugs 0.000 abstract 3
- 229940127088 antihypertensive drug Drugs 0.000 abstract 2
- 230000036772 blood pressure Effects 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 230000036626 alertness Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000009931 harmful effect Effects 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 230000000422 nocturnal effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000033764 rhythmic process Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Indole Compounds (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με ένα φαρμακευτικό σκεύασμα, το οποίο περιέχει και μελατονίνη και τουλάχιστον μία αντιυπερτασική ένωση, καθώς και με μία μέθοδο, για τη θεραπευτική αντιμετώπιση σε ασθενείς οι οποίοι παρουσιάζουν αντίσταση στα αντιυπερτασικά φάρμακα απουσία μελατονίνης, με μία μέθοδο για τη μείωση της νυκτερινής αρτηριακής πίεσης σε ασθενείς οι οποίοι δεν έχουν φυσιολογικό ρυθμό της αρτηριακής πίεσης απουσία ή παρουσία αντιυπερτασικών φαρμάκων, και με μία μέθοδο η οποία προσφέρει στους ασθενείς τουλάχιστον μία δράση η οποία επιλέγεται από τη βελτίωση της ψυχικής διάθεσης και της εγρήγορσης κατά τη διάρκεια της ημέρας, την επιβράδυνση του χρόνου του ανωτάτου επιπέδου της κορτιζόλης στους ασθενείς και με την πιθανή προφύλαξη από τα επιβλαβή αποτελέσματα της καρδιακής ισχαιμίας, στην οποία μέθοδο η μελατονίνη χορηγείται σε μία αποτελεσματική ποσότητα και με έναν αποτελεσματικό τρόπο.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IL2000/000009 WO2001049286A1 (en) | 2000-01-05 | 2000-01-05 | Method and formulation for treating resistance to antihypertensives and related conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108018T1 true CY1108018T1 (el) | 2011-04-06 |
Family
ID=11042938
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071100916T CY1108018T1 (el) | 2000-01-05 | 2007-07-10 | Μεθοδος και φαρμακευτικο σκευασμα για την αντιμετωπιση της αντιστασης στα αντιυπερτασικα φαρμακα και για σχετικες παθησεις |
CY200700033C CY2007033I2 (el) | 2000-01-05 | 2007-12-18 | Μεθοδος και φαρμακευτικο σκευασμα για την αντιμετωπιση της αντιστασης στα αντιυπερτασικα φαρμακα και για σχετικες παθησεις |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY200700033C CY2007033I2 (el) | 2000-01-05 | 2007-12-18 | Μεθοδος και φαρμακευτικο σκευασμα για την αντιμετωπιση της αντιστασης στα αντιυπερτασικα φαρμακα και για σχετικες παθησεις |
Country Status (31)
Country | Link |
---|---|
US (3) | US7332177B1 (el) |
EP (1) | EP1272177B1 (el) |
JP (1) | JP4996803B2 (el) |
CN (1) | CN1414851A (el) |
AT (1) | ATE359072T1 (el) |
AU (1) | AU782266B2 (el) |
BG (1) | BG65637B1 (el) |
BR (1) | BR0016918A (el) |
CA (1) | CA2396129C (el) |
CY (2) | CY1108018T1 (el) |
CZ (1) | CZ299931B6 (el) |
DE (1) | DE60034373T2 (el) |
DK (1) | DK1272177T3 (el) |
EA (1) | EA004679B1 (el) |
EE (1) | EE200200379A (el) |
ES (1) | ES2284471T3 (el) |
HK (1) | HK1052655A1 (el) |
HU (1) | HU227002B1 (el) |
IL (1) | IL150190A0 (el) |
IS (1) | IS6439A (el) |
MX (1) | MXPA02005783A (el) |
NO (1) | NO322567B1 (el) |
NZ (1) | NZ520078A (el) |
PL (1) | PL201219B1 (el) |
PT (1) | PT1272177E (el) |
SI (1) | SI1272177T1 (el) |
SK (1) | SK287508B6 (el) |
TR (1) | TR200201724T2 (el) |
TW (1) | TWI260983B (el) |
UA (1) | UA77394C2 (el) |
WO (1) | WO2001049286A1 (el) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL144900A (en) * | 2001-08-14 | 2013-12-31 | Neurim Pharma 1991 | Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs |
IL155666A (en) | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Insomnia treatment |
US9119846B2 (en) | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
US20050020666A1 (en) * | 2003-07-25 | 2005-01-27 | Dabur Research Foundation | Cardioprotective agents |
US20050137247A1 (en) * | 2003-12-22 | 2005-06-23 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of hypertension |
JP3964417B2 (ja) | 2004-09-27 | 2007-08-22 | 国立大学法人金沢大学 | インドール誘導体を有効成分とするα2受容体遮断剤及び血管拡張剤 |
KR101053780B1 (ko) * | 2008-02-29 | 2011-08-02 | 동아제약주식회사 | 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물 |
EP2633376A4 (en) * | 2010-10-25 | 2015-02-18 | Uico Inc | CONTROL SYSTEM WITH A SOLID-RESISTANT TOUCH SENSOR FOR COMPLEX SURFACE GEOMETRY |
WO2012103411A2 (en) | 2011-01-28 | 2012-08-02 | Zx Pharma, Llc | Controlled-release melatonin composition and related methods |
US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
CN109862826B (zh) * | 2016-08-18 | 2023-03-21 | 皇家飞利浦有限公司 | 血压管理 |
EP3777842A1 (en) | 2016-10-31 | 2021-02-17 | Neurim Pharmaceuticals Ltd. | Melatonin mini-tablets and method of manufacturing the same |
US10849856B2 (en) | 2016-10-31 | 2020-12-01 | Neurim Pharmaceuticals Ltd. | Melatonin mini-tablets and method of manufacturing the same |
WO2019038586A1 (en) | 2017-08-19 | 2019-02-28 | Ftf Pharma Private Limited | PHARMACEUTICAL COMPOSITION OF MELATONIN |
ES2724933A1 (es) * | 2018-03-13 | 2019-09-17 | Ocupharm Diagnostics Sl | Terapia combinada con melatonina para la reducción de la presión intraocular |
GB2617102A (en) * | 2022-03-29 | 2023-10-04 | John Hemming Trading Ltd | Sleep therapy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69229490T2 (de) * | 1991-05-09 | 2000-02-17 | Neurim Pharma 1991 | Melatonin enthaltende Arzneimittel |
JPH07503232A (ja) | 1991-10-18 | 1995-04-06 | アルザ・コーポレーション | メラトニンの制御経皮投与 |
US5646049A (en) * | 1992-03-27 | 1997-07-08 | Abbott Laboratories | Scheduling operation of an automated analytical system |
SG41955A1 (en) * | 1992-04-07 | 1997-08-15 | Neurim Pharma 1991 | Use of melatonin for the manufacture of a medicament for the treatment of benign prostatic hyperplasia |
WO1995002068A1 (fr) * | 1993-07-09 | 1995-01-19 | Wakunaga Seiyaku Kabushiki Kaisha | Methode de discrimination des acides nucleiques et necessaire d'essai a cette fin |
PL183148B1 (pl) | 1995-02-01 | 2002-05-31 | Neurim Pharma 1991 | Zastosowanie melatoniny do wytwarzania leku do leczenia zależności, nałogu stosowania lub tolerancji na benzodiazepiny oraz zastosowanie melatoniny do wytwarzania leku do zapobiegania zależności, nałogu stosowania lub tolerancji na benzodiazepiny |
US5648727A (en) * | 1995-10-24 | 1997-07-15 | Dpc Cirrus Inc. | Capacitive level sensing pipette probe |
US5700828A (en) | 1995-12-07 | 1997-12-23 | Life Resuscitation Technologies, Inc. | Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions |
AU2583397A (en) * | 1996-04-10 | 1997-10-29 | Chronorx, Llc | Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions |
RU2134108C1 (ru) | 1998-10-06 | 1999-08-10 | Заславская Рина Михайловна | Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии |
-
2000
- 2000-01-05 BR BR0016918-8A patent/BR0016918A/pt not_active IP Right Cessation
- 2000-01-05 AT AT00900110T patent/ATE359072T1/de active
- 2000-01-05 PL PL356325A patent/PL201219B1/pl unknown
- 2000-01-05 ES ES00900110T patent/ES2284471T3/es not_active Expired - Lifetime
- 2000-01-05 TR TR2002/01724T patent/TR200201724T2/xx unknown
- 2000-01-05 JP JP2001549654A patent/JP4996803B2/ja not_active Expired - Lifetime
- 2000-01-05 EE EEP200200379A patent/EE200200379A/xx unknown
- 2000-01-05 SK SK973-2002A patent/SK287508B6/sk not_active IP Right Cessation
- 2000-01-05 IL IL15019000A patent/IL150190A0/xx unknown
- 2000-01-05 DE DE60034373T patent/DE60034373T2/de not_active Expired - Lifetime
- 2000-01-05 US US10/169,467 patent/US7332177B1/en not_active Expired - Lifetime
- 2000-01-05 PT PT00900110T patent/PT1272177E/pt unknown
- 2000-01-05 SI SI200030958T patent/SI1272177T1/sl unknown
- 2000-01-05 NZ NZ520078A patent/NZ520078A/en not_active IP Right Cessation
- 2000-01-05 CN CN00818153A patent/CN1414851A/zh active Pending
- 2000-01-05 AU AU18882/00A patent/AU782266B2/en not_active Expired
- 2000-01-05 HU HU0204089A patent/HU227002B1/hu unknown
- 2000-01-05 WO PCT/IL2000/000009 patent/WO2001049286A1/en active IP Right Grant
- 2000-01-05 EA EA200200738A patent/EA004679B1/ru not_active IP Right Cessation
- 2000-01-05 CA CA2396129A patent/CA2396129C/en not_active Expired - Lifetime
- 2000-01-05 MX MXPA02005783A patent/MXPA02005783A/es active IP Right Grant
- 2000-01-05 CZ CZ20022346A patent/CZ299931B6/cs not_active IP Right Cessation
- 2000-01-05 DK DK00900110T patent/DK1272177T3/da active
- 2000-01-05 EP EP00900110A patent/EP1272177B1/en not_active Expired - Lifetime
- 2000-05-01 UA UA2002076326A patent/UA77394C2/uk unknown
-
2001
- 2001-07-10 TW TW090116904A patent/TWI260983B/zh not_active IP Right Cessation
-
2002
- 2002-06-24 IS IS6439A patent/IS6439A/is unknown
- 2002-06-27 NO NO20023102A patent/NO322567B1/no not_active IP Right Cessation
- 2002-08-05 BG BG106978A patent/BG65637B1/bg unknown
-
2003
- 2003-07-11 HK HK03105037.1A patent/HK1052655A1/zh unknown
-
2007
- 2007-07-10 CY CY20071100916T patent/CY1108018T1/el unknown
- 2007-12-04 US US11/950,039 patent/US8075914B2/en not_active Expired - Fee Related
- 2007-12-18 CY CY200700033C patent/CY2007033I2/el unknown
-
2011
- 2011-10-25 US US13/281,212 patent/US8728511B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108018T1 (el) | Μεθοδος και φαρμακευτικο σκευασμα για την αντιμετωπιση της αντιστασης στα αντιυπερτασικα φαρμακα και για σχετικες παθησεις | |
CY1115117T1 (el) | Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα | |
CY1116494T1 (el) | Θεραπευτικη αγωγη θρομβοεμβολικων διαταραχων με ριβαροξαβανη | |
CY1118429T1 (el) | Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου | |
CY1118651T1 (el) | Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη | |
CY1117656T1 (el) | Επιλογες θεραπειας για τη νοσο του fabry | |
NO990912D0 (no) | Terapeutiske kombinasjoner av PAR-antagonister og RXR-antagonister og deres anvendelse | |
NO20014842L (no) | Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft | |
CY1112689T1 (el) | Συνθεση για τη βελτιωση της γνωσης και της μνημης | |
EA200401070A1 (ru) | Способы лечения сосудистых заболеваний | |
CY1111471T1 (el) | Μεθοδοι για τον καθαρισμο trans-(-)-δ9-τετραϋδροκανναβινολης και trans-(+)-δ9 τετραϋδροκανναβινολης | |
DE60222137D1 (de) | Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen | |
DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
DE602005009176D1 (de) | Behandlung von t-zellen-lymphom mittels 10-propargyl-10-deazaaminopterin | |
CY1106634T1 (el) | Θεραπευτικα παραγωγα της πιπεραζινης | |
CY1118924T1 (el) | Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας | |
NO20045056L (no) | Fremgangsmater for behandling av hepatitt | |
CY1108629T1 (el) | Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου | |
EA200500782A1 (ru) | Лечение геморрагического шока | |
CY1115690T1 (el) | Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων | |
DE69814394D1 (de) | Verwendung von levobupivacain | |
NO20031410D0 (no) | Antitumorterapi innbefattende distamycinderivater | |
EA200500427A1 (ru) | Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями | |
DE60204694D1 (de) | Kombinationstherapie zur behandlung von herzinsuffizienz | |
HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására |